Pilar Llamas Sillero-rekin lankidetzan egindako argitalpenak (21)

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

    Research and Practice in Thrombosis and Haemostasis, Vol. 5, Núm. 1, pp. 168-178

  4. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

2020

  1. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  2. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

    Journal of Internal Medicine, Vol. 287, Núm. 1, pp. 32-41

  3. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

    Thrombosis Update, Vol. 1

  4. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 8, Núm. 3, pp. 353-359.e1

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  2. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  3. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

  4. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism

    Internal and Emergency Medicine

2018

  1. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

    Journal of Thrombosis and Thrombolysis, Vol. 46, Núm. 4, pp. 551-558

  2. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis

    Thrombosis Research, Vol. 164, pp. 69-74

  3. Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants

    Clinical Pharmacology and Therapeutics, Vol. 103, Núm. 4, pp. 684-691

2017

  1. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

    Research and Practice in Thrombosis and Haemostasis, Vol. 1, Núm. 2, pp. 172-179

  2. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

    Chest, Vol. 151, Núm. 3, pp. 564-571

  3. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

    American Journal of Medicine, Vol. 130, Núm. 4, pp. 482.e1-482.e9

  4. Predictors of active cancer thromboembolic outcomes: RIETE experience of the Khorana score in cancer-associated thrombosis

    Thrombosis and Haemostasis, Vol. 117, Núm. 6, pp. 1192-1198